Beth Faiman, PhD, CNP

Beth Faiman, CNP, PhD, presents the case of a 76-year-old woman with multiple myeloma who experienced cytokine release syndrome (CRS) following CAR T-cell therapy.

Experts on multiple myeloma discuss how they educate and prepare patients who are going to receive CAR T-cell therapy and provide clinical insights on transitioning patients to community practices following treatment.

A panel of experts on multiple myeloma give an overview of unique challenges in managing adverse effects associated with CAR T-cell therapy as compared with other cancer therapies.

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Expert panelists in multiple myeloma share their experiences with implementing bispecifics and transition of care in the community setting for patients with R/R MM.

The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.

Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

Dr Jeremy Larsen reviews data from the MonumenTAL-1 study investigating the CD3- and GPRC5D-targeting bispecific antibody talquetamab in relapsed/refractory multiple myeloma.

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.